[Insert Table 3]
Among COVID-19 patients with hypertension, 169 in 871 patients exposed to ACEIs/ARBs, and 430 in 2,041 unexposed to ACEIs/ARBs died with COVID-19. Whereas, 95 in 433 patients exposed to ACEIs/ARBs, and 274 in 1,428 unexposed to ACEIs/ARBs developed a severe/critical COVID-19 disease. The estimated pooled relative risk of mortality and pooled relative risk of disease severity was 0.73 (95% CI: 0.63-0.86) and 0.72 (95% CI: 0.46-1.12), respectively (Table 2 & Table 3 ). The overall absolute risk reduction of mortality associated with ACEI/ARB among COVID-19 patients was 6.7%. The ‘numbers needed to treat to benefit’ was 15, suggesting that every 15 patients exposed to ACIEs/ARBs may prevent an additional death.